1. Product
Overview
1.1. Market
Definition
1.2. Scope
of the Market
1.2.1. Markets
Covered
1.2.2. Years
Considered for Study
1.2.3. Key
Market Segmentations
2. Research
Methodology
2.1. Objective
of the Study
2.2. Baseline
Methodology
2.3. Key
Industry Partners
2.4. Major
Association and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data
Triangulation & Validations
2.7. Assumptions
and Limitations
3. Executive
Summary
3.1. Overview
of the Market
3.2. Overview
of Key Market Segmentations
3.3. Overview
of Key Market Players
3.4. Overview
of Key Regions/Countries
3.5. Overview
of Market Drivers, Challenges, Trends
4. Voice
of Customer
5. Global
Oncology Drugs Market Outlook
5.1. Market
Size & Forecast
5.1.1. By
Value
5.2. Market
Share & Forecast
5.2.1. By
Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others)
5.2.2. By
Route of Administration (Oral, Parenteral, Others)
5.2.3. By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.4. By
Region
5.2.5. By
Company (2023)
5.3. Market
Map
6. North
America Oncology Drugs Market Outlook
6.1. Market
Size & Forecast
6.1.1. By
Value
6.2. Market
Share & Forecast
6.2.1.
By Drug Class
6.2.2. By Route
of Administration
6.2.3.
By Distribution Channel
6.2.4. By
Country
6.3. North
America: Country Analysis
6.3.1. United
States Oncology Drugs Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Drug Class
6.3.1.2.2.
By Route of Administration
6.3.1.2.3.
By Distribution Channel
6.3.2. Canada
Oncology Drugs Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Drug Class
6.3.2.2.2.
By Route of Administration
6.3.2.2.3.
By Distribution Channel
6.3.3. Mexico
Oncology Drugs Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Drug Class
6.3.3.2.2.
By Route of Administration
6.3.3.2.3.
By Distribution Channel
7. Europe
Oncology Drugs Market Outlook
7.1. Market
Size & Forecast
7.1.1. By
Value
7.2. Market
Share & Forecast
7.2.1. By
Drug Class
7.2.2. By
Route of Administration
7.2.3. By
Distribution Channel
7.2.4. By
Country
7.3. Europe:
Country Analysis
7.3.1. Germany
Oncology Drugs Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Class
7.3.1.2.2.
By Route of Administration
7.3.1.2.3.
By Distribution Channel
7.3.2. United
Kingdom Oncology Drugs Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Class
7.3.2.2.2.
By Route of Administration
7.3.2.2.3.
By Distribution Channel
7.3.3. Italy
Oncology Drugs Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecasty
7.3.3.2.1.
By Drug Class
7.3.3.2.2.
By Route of Administration
7.3.3.2.3.
By Distribution Channel
7.3.4. France
Oncology Drugs Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Drug Class
7.3.4.2.2.
By Route of Administration
7.3.4.2.3.
By Distribution Channel
7.3.5. Spain
Oncology Drugs Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Drug Class
7.3.5.2.2.
By Route of Administration
7.3.5.2.3.
By Distribution Channel
8. Asia-Pacific
Oncology Drugs Market Outlook
8.1. Market
Size & Forecast
8.1.1. By
Value
8.2. Market
Share & Forecast
8.2.1. By
Drug Class
8.2.2. By Route
of Administration
8.2.3. By
Distribution Channel
8.2.4. By
Country
8.3. Asia-Pacific:
Country Analysis
8.3.1. China
Oncology Drugs Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Class
8.3.1.2.2.
By Route of Administration
8.3.1.2.3.
By Distribution Channel
8.3.2. India
Oncology Drugs Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Class
8.3.2.2.2.
By Route of Administration
8.3.2.2.3.
By Distribution Channel
8.3.3. Japan
Oncology Drugs Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Class
8.3.3.2.2.
By Route of Administration
8.3.3.2.3.
By Distribution Channel
8.3.4. South
Korea Oncology Drugs Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Drug Class
8.3.4.2.2.
By Route of Administration
8.3.4.2.3.
By Distribution Channel
8.3.5. Australia
Oncology Drugs Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Drug Class
8.3.5.2.2.
By Route of Administration
8.3.5.2.3.
By Distribution Channel
9. South
America Oncology Drugs Market Outlook
9.1. Market
Size & Forecast
9.1.1. By
Value
9.2. Market
Share & Forecast
9.2.1. By
Drug Class
9.2.2. By
Route of Administration
9.2.3. By
Distribution Channel
9.2.4. By
Country
9.3. South
America: Country Analysis
9.3.1. Brazil
Oncology Drugs Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Class
9.3.1.2.2.
By Route of Administration
9.3.1.2.3.
By Distribution Channel
9.3.2. Argentina
Oncology Drugs Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Drug Class
9.3.2.2.2.
By Route of Administration
9.3.2.2.3.
By Distribution Channel
9.3.3. Colombia
Oncology Drugs Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Drug Class
9.3.3.2.2.
By Route of Administration
9.3.3.2.3.
By Distribution Channel
10. Middle
East and Africa Oncology Drugs Market Outlook
10.1.
Market Size & Forecast
10.1.1. By
Value
10.2.
Market Share & Forecast
10.2.1. By
Drug Class
10.2.2. By
Route of Administration
10.2.3. By
Distribution Channel
10.2.4. By
Country
10.3.
MEA: Country Analysis
10.3.1. South
Africa Oncology Drugs Market Outlook
10.3.1.1. Market
Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market
Share & Forecast
10.3.1.2.1.
By Drug Class
10.3.1.2.2.
By Route of Administration
10.3.1.2.3.
By Distribution Channel
10.3.2. Saudi
Arabia Oncology Drugs Market Outlook
10.3.2.1. Market
Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market
Share & Forecast
10.3.2.2.1.
By Drug Class
10.3.2.2.2.
By Route of Administration
10.3.2.2.3.
By Distribution Channel
10.3.3. UAE Oncology
Drugs Market Outlook
10.3.3.1. Market
Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market
Share & Forecast
10.3.3.2.1.
By Drug Class
10.3.3.2.2.
By Route of Administration
10.3.3.2.3.
By Distribution Channel
11. Market
Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market
Trends & Developments
12.1.
Merger & Acquisition (If Any)
12.2.
Product Launches (If Any)
12.3.
Recent Developments
13. Porters
Five Forces Analysis
13.1.
Competition in the Industry
13.2.
Potential of New Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute Products
14. Competitive
Landscape
14.1.
Astellas Pharma Inc.
14.1.1. Business
Overview
14.1.2. Company
Snapshot
14.1.3. Products
& Services
14.1.4. Financials
(As Reported)
14.1.5. Recent
Developments
14.1.6. Key
Personnel Details
14.1.7. SWOT
Analysis
14.2.
Pfizer, Inc.
14.3.
Novartis AG
14.4.
Astrazeneca Plc
14.5.
Merck & Co., Inc.
14.6.
F. Hoffmann-La Roche Ltd.
14.7.
Amgen, Inc.
14.8.
Bristol-Myers Squibb Company
14.9.
Abbvie Inc.
14.10.
Johnson & Johnson
15. Strategic
Recommendations
16. About
Us & Disclaimer